Nilsine Partners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Nilsine Partners’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.61M	Buy	+16,556	New	+$1.55M	0.11%	170

Other funds holding PBE

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.93B AUM 18.7% 1-Year Est. Return

YHB Investment Advisors West Hartford, Connecticut $1.59B AUM 21.04% 1-Year Est. Return

Penobscot Investment Management Boston, Massachusetts $1.44B AUM 23.59% 1-Year Est. Return

Massachusetts Wealth Management North Andover, Massachusetts $248M AUM 37.44% 1-Year Est. Return

Outlook Wealth Advisors Shenandoah, Texas $470M AUM 20.06% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Newman Dignan & Sheerar Inc Providence, Rhode Island $525M AUM 18.66% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Nilsine Partners's PBE Position: Q3 2026 in Review

Nilsine Partners opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q3 2026: 16,556 shares worth $1.61M. The stake represents 0.11% of the portfolio and ranks #170 among its holdings.

37 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

Nilsine Partners held 16,556 shares of Invesco Biotechnology & Genome ETF worth $1.61M as of Q3 2026.
Invesco Biotechnology & Genome ETF was a new Nilsine Partners position in Q3 2026.
Invesco Biotechnology & Genome ETF made up 0.11% of Nilsine Partners's portfolio in Q3 2026, its #170 holding.
37 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Nilsine Partners's 13F filing for Q3 2026, filed 2 Nov 2026.